drugset / Trial / NCT06128629
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Timeline
- Start
- 2023-12-13
- Primary completion
- 2027-12
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NTLA-2001 | CRISPR / gene editing | 55 mg | Intravenous |
Indications
No indication recorded.